Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)

NCT05769595 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

End-Stage Renal Disease (ESRD)
End-Stage Kidney Disease (ESKD)
Kidney Failure, Chronic

Interventions

BIOLOGICAL: MK-2060
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC